2025
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial
Somé A, Somé A, Sougué E, Ouédraogo C, Da O, Dah S, Nikièma F, Magalhaes T, Gray L, Finical W, Pugh G, Lado P, Randall J, Burton T, Ring M, Leon A, Colt M, Li F, Wang K, Wade M, Lier A, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson C, Xiao M, Wu E, Bousema T, Slater H, Foy B, Parikh S, Dabiré R. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. The Lancet Infectious Diseases 2025, 25: 737-750. PMID: 39919778, DOI: 10.1016/s1473-3099(24)00751-5.Peer-Reviewed Original ResearchSeasonal malaria chemopreventionIvermectin mass drug administrationEntomological inoculation rateMalaria incidenceParallel-group trialMass drug administrationDouble-blindPlacebo-ControlledControl groupAdverse eventsPrimary outcomeWeekly active case detectionDrug AdministrationLow malaria incidenceIntervention groupReducing malaria incidenceMalaria-endemic regionsMalaria incidence ratesRisk of adverse eventsInoculation rateNational Institute of AllergyPan African Clinical Trials RegistryComplementary vector control toolsCluster-randomisedInstitute of Allergy
2024
Impact of a multicomponent strategy including decentralized molecular testing for tuberculosis on mortality: planned analysis of a cluster-randomized trial in Uganda
Katamba A, Mochizuki T, Nalugwa T, Nantale M, Oyuku D, Nabwire S, Babirye D, Musinguzi J, Nakawesa A, Nekesa I, Turyahabwe S, Joloba M, Dowdy D, Moore D, Davis J, Shete P, Adams K, Reza T, Fielding K, Cattamanchi A. Impact of a multicomponent strategy including decentralized molecular testing for tuberculosis on mortality: planned analysis of a cluster-randomized trial in Uganda. EClinicalMedicine 2024, 78: 102953. PMID: 39659443, PMCID: PMC11629260, DOI: 10.1016/j.eclinm.2024.102953.Peer-Reviewed Original ResearchCommunity health centersCluster randomized trialHealth centersPragmatic cluster randomized trialMulticomponent strategiesSix-month mortality riskSecondary outcomesPan African Clinical Trials RegistryCluster-level analysisPatient-level covariatesAll-Cause MortalityClinical Trials RegistryIntervention armSub-group analysisTB careMortality risk analysisRoutine careVital statusTrial armsMagnitude of effectPresumptive TBRate ratiosProximal outcomesTrial participantsUS National Institutes
2018
Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Drugs T, Sagara I, Beavogui A, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Traore A, Diallo N, Diakite H, Togo A, Koumare S, Keita M, Camara D, Somé A, Coulibaly A, Traore O, Dama S, Goita S, Djimde M, Bamadio A, Dara N, Maiga H, Sidibe B, Dao F, Coulibaly M, Alhousseini M, Niangaly H, Sangare B, Diarra M, Coumare S, Kabore M, Ouattara S, Barry A, Kargougou D, Diarra A, Henry N, Soré H, Bougouma E, Thera I, Compaore Y, Sutherland C, Sylla M, Nikiema F, Diallo M, Dicko A, Picot S, Borrmann S, Duparc S, Miller R, Doumbo O, Shin J, Gil J, Björkman A, Ouedraogo J, Sirima S, Djimde A. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. The Lancet 2018, 391: 1378-1390. PMID: 29606364, PMCID: PMC5889791, DOI: 10.1016/s0140-6736(18)30291-5.Peer-Reviewed Original ResearchConceptsArtemisinin-based combination therapyFirst-line artemisinin-based combination therapyArtemether-lumefantrineDay 28Day 42Study drugUncomplicated malariaMalaria episodesEligible participantsIncidence ratePan African Clinical Trials RegistryUncomplicated P falciparum malariaCurrent first-line therapyAfrican Clinical Trials RegistryDeveloping Countries Clinical Trials PartnershipDihydroartemisinin-piperaquine treatmentFirst malaria episodeP falciparum malariaUncomplicated malaria episodesFirst-line therapyHistory of feverClinical Trials RegistryNon-falciparum speciesMild transient elevationUK Medical Research Council
2012
Sanitary Pad Interventions for Girls' Education in Ghana: A Pilot Study
Montgomery P, Ryus CR, Dolan CS, Dopson S, Scott LM. Sanitary Pad Interventions for Girls' Education in Ghana: A Pilot Study. PLOS ONE 2012, 7: e48274. PMID: 23118968, PMCID: PMC3485220, DOI: 10.1371/journal.pone.0048274.Peer-Reviewed Original ResearchConceptsPuberty educationGirls' educationSchool attendanceEducation of girlsSecondary educationEducationDevelopment needsAttendance levelsEducation interventionEvents of menarcheGirls transitionSanitary padsAttendancePilot studyPan African Clinical Trials RegistryAfrican Clinical Trials RegistryPAD interventionsClinical Trials RegistryNon-randomized trialsContextPositive healthProvisionGhanaSchoolgirlsParticipants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply